TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC(0-T))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Possession Ratio (MPR) During First 180 Days of Treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Who Discontinued Treatment in the First 90 Days From the Index Date
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Recurrence During the Acute Treatment Phase
Endpoint domain: Adverse events/effects
Primary endpoint: DAS-28-CRP score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of notes accessed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 12-month Leukaemia Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Microbiome activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nutritional follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: major cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adjudicated On-trial annualized relapse rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood cortisol change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lens Fit Acceptance Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain score after injection at perineal laceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychiatric functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in perceived quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: levels of anti-nephrin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent of time with ≥70% erection during overnight sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Nutritional status risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-t of ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUC0-t of total ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax of total ursodeoxycholic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sheath-to-first device activation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of NGAL in diagnosing IBD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Michigan neuropathy screening instrument (MNSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biothesiometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: NeuroQoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: incidence of hypothyroidism after TAVI procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Accuracy in implicit learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who experience early adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants who experience late adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: change in arm impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications after extracorporeal circulation cardiac surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability as defined as tolerable dose
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as defined by frequency of toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: clinical profile and outcome in Takotsubo Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in semen analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in seminal oxidative status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in serum testosterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Serum Magnesium Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in number of silent cerebral ischemia (SBI) foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in volume of silent cerebral ischemia (SBI) foci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in anterior-to-posterior abdominal measurement immediately after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anterior-to-posterior abdominal measurement 5 minutes after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vitamin D sulfate levels in breastmilk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: JAMAR Hydraulic hand Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Psychological Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Visual tumor conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BI-RADS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Diagnosis of Venous Thromboembolism
Endpoint domain: Mortality/survival
Primary endpoint: Change in DENV neutralizing antibody GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean peak viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Frequency and severity of reactogenicity signs and symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Digital biomarker estimations for apathy, agitation, pain, and sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: [18F]-FDOPA SUVr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [18F]-FEOBV SUVr
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in external glenohumeral joint rotations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Craniovertebral Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diffusion capacity for carbon monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum oxidative stress biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting serum bile acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting serum lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gaze Stabilization Test (GST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of MGUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained MRD negative remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional tests
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cognitive tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: EQ-Visual Analog Score (EQ-VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mental Rotation Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perspective Taking Ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Variations of lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patients' compliance with scheduled endoscopic exam and questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants achieving diabetes remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants achieving significant weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopic Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in cancer-related fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: System Usability Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Favorable evolution of the CAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AKI (Acute Kidney Injury)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Culture success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified pediatric early warning score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with at least one adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving at least moderate improvement in Total Improvement Score (TIS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Visualization and quantification of cerebral perfusion with CEUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visualization and quantification of renal perfusion with CEUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Smoking Abstinence CO Reading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking Abstinence Self Reported
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Polycystic Ovary Syndrome Quality of Life scale score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: safety of the autologous FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Mitochondrial physiology in the oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Antibody Titer for Post Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion Rate for Post Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sleep in the ICU
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Visual Reaction Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Reaction Time Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posture stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in body composition-muscular element
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in body composition-fat element
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in body composition-extreacellular oedema element
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term hip function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Incontinence Inquiry Form ICIQ-SF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pad test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between Senseye DT and CAPS-5-R assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient scar satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of new diagnoses for CKD, creatinine tests and/or albuminuria tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: occurrence of immune-related adverse event (irAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of M4344 and Niraparib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adequate analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in psychological state
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ankle balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearance/Efficacy of the AUR-201 Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trabecular Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bone Strength (Failure load)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Soft tissue pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain to percussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyadic Sexual Communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Response Rate in ADC1 (Group 1) Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response Rate in ADC2 (Group 2) Cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cross-sectional area (ACSA) postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rates at 2-months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Retention rates at 4-months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adapted system usability scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Peak C-peptide during Mixed-Meal Tolerance Test (MMTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: improvement of symptoms of AD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain Region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale-2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Carolinas Comfort Scale values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: normal anterior occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: no anterior crossbite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normal measured Overjet and Overbite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, relatedness and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum pain intensity in the first 3 hours of HAIC treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New or worsening depression or anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unmet mental health care needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in proportion of LTCF residents with ADRD and diabetes using high risk medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety severity in children (SCARED-child)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety severity in children (SCARED-parent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of anxiety in children (SCID-parent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in severity of anxiety in children (SCID-child)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between diagnostic approaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes to cognitive and emotional perception of illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of PPAP
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of unplanned ICU admissions and hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of IgG Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probability of identifying IPDA within 1 cm of anticipated location
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Endothelial biomarker measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffusion Capacity (DLCO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effectiveness of cleaning during colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: urinary incontinence severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Depression Literacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Positive vs Negative Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of environmental sound cues correctly identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of smell and taste disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to disease improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieving the Patient Acceptable Symptom State (PASS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence/absence of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and severity of adverse events (CTCAE classification)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases of early termination of participation due to Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Stimulation efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graded Redefined Assessment of Strength Sensibility and Prehension (GRASSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen-Taylor hand function test (JTHFT-IT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand Grip Dynamometer Strength Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amygdala cerebral blood flow during Blue vs Red light exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ventral Striatum cerebral blood flow during Blue vs Red light exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amygdala activity (loss>neutral) during Blue vs Red light exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ventral Striatum activity (punish>neutral) during Blue vs Red light exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum sorbitol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Neuropathy Limitations Scale (ONLS) scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Grief Reactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to FSGS Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Time to Graft Failure
Endpoint domain: Mortality/survival
Primary endpoint: Brain Glutamate Dynamic Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Radial Artery Occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes